Metolazone and Furosemide Combination in Cardiorenal Syndrome: Short-Term Safety and Efficacy Among Admitted Patients in a Tertiary Hospital

Background: Diuretics are considered one of the essential drugs in the management, wherein Furosemide is usually given. But in some cases, it can be ineffective due to diuretic resistance. Metolazone is a thiazide-like diuretic, can be combined with loop diuretics to control volume overload. Since the drug is just newly introduced in our country, this study examines the immediate effect of Metolazone-Furosemide combination and possible adverse reactions in patients with Cardiorenal Syndrome.

[1]  N. Bayley,et al.  Failure , 1890, The Hospital.

[2]  R. Gunstone,et al.  Clinical experience with metolazone in fifty-two African patients: synergy with frusemide , 1971, Postgraduate medical journal.

[3]  C. Swartz,et al.  The acute effects of metolazone on electrolyte and acid excretion in man , 1972, Clinical pharmacology and therapeutics.

[4]  J. Arruda,et al.  Metolazone and spironolactone in cirrhosis and the nephrotic syndrome , 1977, Clinical pharmacology and therapeutics.

[5]  J. Bamford.  Synergistic action of metolazone with "loop" diuretics. , 1981, British medical journal.

[6]  E. Garin.  A comparison of combinations of diuretics in nephrotic edema. , 1987, American journal of diseases of children.

[7]  K. Channer,et al.  Combination diuretic treatment in severe heart failure: a randomised controlled trial. , 1994, British heart journal.

[8]  C. O'connor,et al.  Diuretic resistance predicts mortality in patients with advanced heart failure. , 2002, American heart journal.

[9]  Bertram L Kasiske,et al.  Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. , 2003, Circulation.

[10]  Bertram L Kasiske,et al.  Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. , 2003, Hypertension.

[11]  D. Sica.  Diuretic‐Related Side Effects: Development and Treatment , 2004, Journal of clinical hypertension.

[12]  V. Hasselblad,et al.  Relation between dose of loop diuretics and outcomes in a heart failure population: Results of the ESCAPE Trial , 2007, European journal of heart failure.

[13]  J. Griffith,et al.  Cardiovascular disease and subsequent kidney disease. , 2007, Archives of internal medicine.

[14]  C. O'connor,et al.  Loop Diuretics in Acute Decompensated Heart Failure: Necessary? Evil? A Necessary Evil? , 2009, Circulation. Heart failure.

[15]  W. Tang,et al.  Cardiorenal syndrome in decompensated heart failure , 2009, Heart.

[16]  R. Bellomo,et al.  Therapeutic strategies for heart failure in cardiorenal syndromes. , 2010, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[17]  C. Ronco,et al.  Volume overload and cardiorenal syndromes. , 2010, Congestive heart failure.

[18]  Adrian F. Hernandez,et al.  Combination of loop diuretics with thiazide-type diuretics in heart failure. , 2010, Journal of the American College of Cardiology.

[19]  Cardio-renal syndromes: report from the consensus conference of the Acute Dialysis Quality Initiative , 2009, European heart journal.

[20]  S. Bagshaw,et al.  Heart-Kidney Interaction: Epidemiology of Cardiorenal Syndromes , 2010, International journal of nephrology.

[21]  M. Weir.  Recognizing the link between chronic kidney disease and cardiovascular disease. , 2011, The American journal of managed care.

[22]  C. Ronco,et al.  The Cardiorenal Syndrome , 2011, International journal of nephrology.

[23]  D. Sica.  Diuretic use in renal disease , 2012, Nature Reviews Nephrology.

[24]  M. Degertekin,et al.  A Single-Centre Study of Acute Cardiorenal Syndrome: Incidence, Risk Factors and Consequences , 2012, Cardiorenal Medicine.

[25]  Bataclan Rp.  Metolazone and Furosemide Combination in Cardiorenal Syndrome: Short-Term Safety and Efficacy Among Admitted Patients in a Tertiary Hospital , 2019, JOJ Urology & Nephrology.